← FDA DRUG APPROVALS

FDA ANDA · ANDA090935

WARFARIN SODIUM

warfarin

Sponsor: INVAGEN PHARMS

APPLICATION
ANDA090935
TYPE
ANDA
ORIGINAL APPROVAL
2011-05-25
LATEST ACTION
2019-09-26
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

WARFARIN SODIUMPrescription
WARFARIN SODIUM 1MG · TABLET · ORAL
WARFARIN SODIUMPrescription
WARFARIN SODIUM 7.5MG · TABLET · ORAL
WARFARIN SODIUMPrescription
WARFARIN SODIUM 5MG · TABLET · ORAL
WARFARIN SODIUMPrescription
WARFARIN SODIUM 3MG · TABLET · ORAL
WARFARIN SODIUMPrescription
WARFARIN SODIUM 2MG · TABLET · ORAL
WARFARIN SODIUMPrescription
WARFARIN SODIUM 10MG · TABLET · ORAL
WARFARIN SODIUMPrescription
WARFARIN SODIUM 6MG · TABLET · ORAL
WARFARIN SODIUMPrescription
WARFARIN SODIUM 4MG · TABLET · ORAL
WARFARIN SODIUMPrescription
WARFARIN SODIUM 2.5MG · TABLET · ORAL

Approval history

2019-09-26Labeling · Supplement 9 · standardAP
2019-09-26Labeling · Supplement 5 · standardAP
2019-09-26Labeling · Supplement 3 · standardAP
2013-08-13Labeling · Supplement 1 · standardAP
2011-05-25OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →